- Home
- STTK
STTK
Shattuck Labs Inc.
as of 02-26-2026 9:32am EST
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 275.9M | IPO Year: | 2020 |
| Target Price: | $6.20 | AVG Volume (30 days): | 375.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | 27.32 |
| 52 Week Low/High: | $0.69 - $4.89 | Next Earning Date: | N/A |
| Revenue: | $5,721,000 | Revenue Growth: | 245.26% |
| Revenue Growth (this year): | -79.2% | Revenue Growth (next year): | N/A |
| P/E Ratio: | -6.53 | Index: | N/A |
| Free Cash Flow: | -60574000.0 | FCF Growth: | N/A |
Compare STTK vs Leading Stocks
See how STTK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.